Evommune (NYSE:EVMN) CEO Luis Pena Sells 7,438 Shares

Evommune, Inc. (NYSE:EVMN) CEO Luis Pena sold 7,438 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the completion of the transaction, the chief executive officer directly owned 630,458 shares in the company, valued at approximately $14,317,701.18. The trade was a 1.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Evommune Trading Down 3.0%

Shares of NYSE EVMN opened at $23.53 on Thursday. Evommune, Inc. has a 12-month low of $13.89 and a 12-month high of $33.20. The firm has a market capitalization of $847.59 million and a price-to-earnings ratio of -2.48. The firm has a 50 day moving average of $23.07 and a 200 day moving average of $22.28.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. Sell-side analysts predict that Evommune, Inc. will post -2.85 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on EVMN shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Wall Street Zen cut Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Oppenheimer started coverage on Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective on the stock. Morgan Stanley boosted their price objective on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Stifel Nicolaus assumed coverage on shares of Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $49.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Capricorn Fund Managers Ltd bought a new stake in Evommune during the fourth quarter valued at about $1,027,000. Sofinnova Investments Inc. bought a new position in shares of Evommune in the fourth quarter worth about $2,625,000. NEXTBio Capital Management LP bought a new position in shares of Evommune in the fourth quarter worth about $3,908,000. Monashee Investment Management LLC purchased a new stake in shares of Evommune during the fourth quarter worth about $3,137,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of Evommune during the fourth quarter worth about $1,284,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.